GeneDx Holdings Corp. (NASDAQ: WGS), a leading provider of cell-free DNA testing solutions, saw its stock surge by 5.47% in the pre-market trading session on Wednesday. This surge followed the company's announcement of its innovation roadmap and advancements in molecular residual disease (MRD) testing and early cancer detection products.
According to the announcement, GeneDx is introducing a new version of its Signatera assay, designed on the whole genome sequence (WGS) of a patient's tumor. This genome-based assay is expected to enhance the company's MRD testing capabilities, building upon the success of its exome-based Signatera assay.
Additionally, GeneDx unveiled a new tissue-free MRD capability, leveraging its expertise in methylation-based technologies. The first launch in this line is expected in mid-2025 for colorectal cancer, with more tumor indications to follow. The company also shared promising early performance data for its early cancer detection (ECD) assay, demonstrating high detection rates for stage 1 colorectal cancer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。